Integrating Multimodal Baseline Biomarkers with Clinical Outcomes in Patients with Cold, Refractory Tumors, Treated with Fc-Enhanced Anti–CTLA-4 Antibody Therapy
- Botensilimab (BOT), a novel Fcenhanced anti–CTLA-4 antibody, alone or combined with balstilimab (BAL; anti– PD-1), has demonstrated promising clinical activity across immunologically “cold” treatment-refractory cancers
- We assessed systemic, tumor, and clinical features of patients treated with BOT±BAL for metastatic treatment-refractory cancers in the phase 1 C-800-01 trial (NCT03860272)
- In cold and treatment-refractory cancers, clinical outcomes with BOT±BAL appear to depend on the balance between detrimental systemic inflammation and beneficial TME immune activity plus peripheral T-cell differentiation, rather than conventional single biomarkers